Q-Med AB Invites to Conference Call Regarding Half Year Report January-June, 2009

STOCKHOLM, Sweden--(Business Wire)--
Regulatory News:

Q-Med AB: (STO:QMED)

Time: Thursday, July 23, 2009 at 11.30 a.m. CET.

To join the conference: Swedish dial in number: + 46 (0)8 5052 0114
UK dial in number: +44 (0)207 1620 177

Q-Med participants: Bengt Ågerup, CEO
Alexander Kotsinas, CFO
Karin Falck, Director Corporate Communications

Q-Med AB`s Q2 report will be released approximately 10.30 on July 23, 2009.

The slide presentation will be available at www.q-med.com, and
Investors/Presentations.

A recorded version of the presentation will be available for seven working days
on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 83 99
40.

Financial information from Q-Med during 2009
23 October Interim Report January - September 2009

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane for filling lines and folds, contouring and creating volume in the
face, Macrolane for body contouring, Durolane for the treatment of
osteoarthritis of the hip and knee joints, Deflux for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
about 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882. Tel: +46 18 474 90 00. Fax: +46 18 474 90 01.
E-mail: info@q-med.com. Web: www.q-med.com.

This information was brought to you by Cision http://www.cisionwire.com

Q-Med AB
Karin Falck, Director Corporate Communications
Tel: +46 70 974 90 15
or
Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 70 974 90 71

Copyright Business Wire 2009